Comparative Pharmacology
Head-to-head clinical analysis: FANSIDAR versus MALMOREDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FANSIDAR versus MALMOREDE.
FANSIDAR vs MALMOREDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fansidar combines sulfadoxine, a sulfonamide dihydrofolate reductase inhibitor, and pyrimethamine, a dihydrofolate reductase inhibitor, synergistically inhibiting folate synthesis in Plasmodium species, leading to nucleic acid synthesis inhibition and parasite death.
Malmorede is a synthetic peptide analog of thymosin alpha 1, acting as a biological response modifier. It enhances T-cell maturation and function, increases interleukin-2 production, and modulates immune response by activating dendritic cells and promoting Th1-type cytokine release.
For acute uncomplicated malaria: 3 tablets (25 mg pyrimethamine + 500 mg sulfadoxine per tablet) orally as a single dose on Day 0 and Day 1 (total 6 tablets); alternatively, 3 tablets as a single dose. For severe malaria: 3 tablets orally as a single dose, repeated at weekly intervals if necessary.
Initial: 50 mg orally twice daily. Maintenance: 100 mg orally once daily.
None Documented
None Documented
Sulfadoxine: 100-200 hours; pyrimethamine: 80-100 hours; clinical context: unusual for antimalarials, allows single-dose therapy for uncomplicated P. falciparum
4-6 hours; increased in renal impairment (up to 12-15 hours).
Renal: sulfadoxine 80% (unchanged), pyrimethamine 20-40% (unchanged); fecal: sulfadoxine <5%, pyrimethamine <5%
Primarily renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Category C
Category C
Antimalarial
Antimalarial